The Center for Biosimilars® recaps the top 5 articles for the week of May 21, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of May 21.
Number 5: Both a disease activity score in a count of 28 joints and a score on a short-form mental health survey may be able to predict which patients with rheumatoid arthritis will experience a disease flare if they try to taper their anti—tumor necrosis factor therapy.
Number 4: The FDA has released a new series of educational videos on biosimilars and interchangeable products.
Number 3: At this week’s International Society for Pharmacoeconomics and Outcomes Research’s (or ISPOR’s) 23rd Annual International Meeting, researchers reported that, while biosimilars have a longer history in Europe than they have in the United States, challenges to uptake still linger.
Number 2: In a Monday workshop at the ISPOR meeting, Mike Blum, MD, MPH, of the FDA, addressed the role of postmarketing surveillance in the US biosimilars market.
Number 1: The European Commission has granted marketing authorization to Sandoz’s infliximab biosimilar, Zessly.
Finally, last week, our e-newsletter asked whether you think that the President’s drug pricing plan goes far enough to address Americans’ concerns over the high cost of healthcare.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.